舒肝益脾胶囊对乙型肝炎肝硬化脾功能亢进的改善作用  

Shugan Yipi capsules improve hypersplenism in patients with hepatitis B cirrhosis

作　　者：陈锦[1] 王新国[1] 黄利华[1] 

机构地区：[1]无锡市第五人民医院肝科,江苏省无锡市214000

出　　处：《世界华人消化杂志》2016年第18期2898-2902,共5页World Chinese Journal of Digestology

摘　　要：目的:评价舒肝益脾胶囊治疗乙型肝炎肝硬化脾功能亢进的疗效.方法:将60例乙型肝炎早期肝硬化肝炎患者随机分为舒肝益脾胶囊(治疗组)和水飞蓟宾葡甲胺(对照组),疗程3 mo,观察两组患者的临床表现、肝功能、血常规、脾静脉主干宽度变化、脾脏横径变化、门静脉血流速度变化、肝脏超声影像和瞬时弹性成像检测(FIBROTOUCH)数值变化.结果:治疗组与对照组比较在降低转氨酶指标及减轻肝纤维化(主要是肝脏超声影像和瞬时弹性成像检测FIBROTOUCH数值变化)上差异无显著性(P>0.05),降低黄疸指数治疗组优于对照组.但对脾脏肿大的改善即脾脏回缩(治疗前后治疗组,对照组脾脏横径变化)有显著性(P<0.05,0.01).结论:舒肝益脾胶囊可作为乙型肝炎肝硬化脾功能亢进较为理想的治疗药物.AIM：To evaluate the therapeutic effect of Shugan Yipi capsules on hypersplenism in patients with hepatitis B cirrhosis.METHODS： Sixty patients with early hepatitisB were randomly divided into a Shugan Yipi capsules group（observation group） and a silybin meglumine group（control group）. After 3 mo of treatment, clinical manifestations, liver function, blood tests, splenic vein trunk width change, spleen diameter change, portal vein blood fl ow change, liver ultrasonic images and FibroT ouch change were compared between the two groups. RESULTS： There were no signifi cant differences in reduced transaminase indicators and liver fibrosis between the two groups（P 0.05）. The reduction in jaundice index in the treatment group was better than that in the control group. The improvement of the spleen retraction was also significantly different between the two groups（P 0.05, 0.01）. CONCLUSION： Shugan Yipi capsules can improve hypersplenism in patients with hepatitis B cirrhosis.

关 键 词：舒肝益脾胶囊 脾功能亢进 肝硬化 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]